Before 2018, the Cochrane Movement Disorders Group prioritisation process resulted mainly from the consultation of the members of the Editorial Board (who ranked the review titles as high, medium or low priority, and proposed new topics)and the evaluation of data on review access and citation.
In 2018, the Cochrane Movement Disorders Group participated in a priority setting process which scope was to identify a list of priority reviews to be conducted in 2019/2020.
This process included two stages:
- A formal prioritisation exercise, based on an online survey
- A consultation of the evidence needs from stakeholders partners
1. The Cochrane Movement Disorders Group and the Cochrane Epilepsy Group had been awarded funding to produce some new and new updated systematic reviews funded by an NIHR Programme grant (NIHR 16/114/26). Therefore, it was important to prioritize our work in view to make the best use of the funding, limited time and resources, selecting important topics and providing the most valuable reviews for stakeholders.
Our steering group involved stakeholders partners, including patients and carers groups, leads and manager of the Cochrane Movement Disorders Group and researchers with experience in systematic reviews.
We participated in an online survey and invited people with experience in Parkinson's disease (people with the condition, carers, family members, care professionals) to answer questions in the survey. We collected their opinion on a shortlist of new reviews or updates, asked for suggestions for new topics and reasons why those topics are important. Although much less detailed, we used a method similar to the James Lind Alliance approach. There was also some engagement with NICE guideline documentation to assess priorities and stakeholders groups. Invitations have circulated on our behalf by interest groups supporting people with the condition and social media. The online survey for Parkinson's disease was launched on September 2018 (deployed via social media, Cochrane Movement Disorders website and Parkinson's UK) and closed on December 2018. From this exercise, a top of five high priority topics was identified:
Drug treatment options in early (after the first diagnosis) Parkinson's disease
Interventions for preventing falls in Parkinson's disease
Nurse specialists for Parkinson's disease
Prognosis for people with newly diagnosed Parkinson's disease
Therapeutic interventions for sleep disorders in Parkinson's disease
2. European Academy of Neurology (EAN) and International Parkinson and Movement Disorders Society (MDS) identified the evidence needs for the purpose of guideline/evidence decisions development. This was established after face-to-face meetings with the Boards of both scientific societies. One topic was identified:
Therapies for depression in Parkinson's disease